Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID-19: disease control as an important factor relative to recent chemotherapy or anti-CD20 therapy

UKCCMP team

doi:10.1111/bjh.17937

Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID-19: disease control as an important factor relative to recent chemotherapy or anti-CD20 therapy

UKCCMP team

Research output: Contribution to journal › Article › peer-review

44 Downloads (Pure)

Abstract

Patients with haematological malignancies have a high risk of severe infection and death from SARS-CoV-2. In this prospective observational study, we investigated the impact of cancer type, disease activity, and treatment in 877 unvaccinated UK patients with SARS-CoV-2 infection and active haematological cancer. The primary end-point was all-cause mortality. In a multivariate analysis adjusted for age, sex and comorbidities, the highest mortality was in patients with acute leukaemia [odds ratio (OR) = 1·73, 95% confidence interval (CI) 1·1-2·72, P = 0·017] and myeloma (OR 1·3, 95% CI 0·96-1·76, P = 0·08). Having uncontrolled cancer (newly diagnosed awaiting treatment as well as relapsed or progressive disease) was associated with increased mortality risk (OR = 2·45, 95% CI 1·09-5·5, P = 0·03), as was receiving second or beyond line of treatment (OR = 1·7, 95% CI 1·08-2·67, P = 0·023). We found no association between recent cytotoxic chemotherapy or anti-CD19/anti-CD20 treatment and increased risk of death within the limitations of the cohort size. Therefore, disease control is an important factor predicting mortality in the context of SARS-CoV-2 infection alongside the possible risks of therapies such as cytotoxic treatment or anti-CD19/anti-CD20 treatments.

Original language	English
Pages (from-to)	892-901
Number of pages	10
Journal	British Journal of Haematology
Volume	196
Issue number	4
Early online date	10 Nov 2021
DOIs	https://doi.org/10.1111/bjh.17937
Publication status	Published - 9 Feb 2022

Bibliographical note

Funding Information:
The work was supported by University of Birmingham, University of Oxford, Blood Cancer UK (#20011). The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. This research was also supported by the National Institute for Health Research (NIHR) infrastructure at Leeds.

Publisher Copyright:
© 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.

Keywords

COVID-19
cancer treatments
haematological malignancies
Hematology
Multiple Myeloma/complications
Prospective Studies
COVID-19/complications
Humans
Risk Factors
Leukemia/complications
Male
Antigens, CD20/immunology
Adult
Female
Hematologic Neoplasms/complications
Antineoplastic Agents, Immunological/adverse effects

ASJC Scopus subject areas

Hematology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/bjh.17937Licence: Creative Commons: Attribution (CC BY)

Br J Haematol - 2021 - Booth - Key findings from the UKCCMP cohort of 877 patients with haematological malignancy andFinal published version, 480 KBLicence: Creative Commons: Attribution (CC BY)

Cite this

@article{fedade752fa34a32a48f5176e63b8365,

title = "Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID-19: disease control as an important factor relative to recent chemotherapy or anti-CD20 therapy",

abstract = "Patients with haematological malignancies have a high risk of severe infection and death from SARS-CoV-2. In this prospective observational study, we investigated the impact of cancer type, disease activity, and treatment in 877 unvaccinated UK patients with SARS-CoV-2 infection and active haematological cancer. The primary end-point was all-cause mortality. In a multivariate analysis adjusted for age, sex and comorbidities, the highest mortality was in patients with acute leukaemia [odds ratio (OR) = 1·73, 95% confidence interval (CI) 1·1-2·72, P = 0·017] and myeloma (OR 1·3, 95% CI 0·96-1·76, P = 0·08). Having uncontrolled cancer (newly diagnosed awaiting treatment as well as relapsed or progressive disease) was associated with increased mortality risk (OR = 2·45, 95% CI 1·09-5·5, P = 0·03), as was receiving second or beyond line of treatment (OR = 1·7, 95% CI 1·08-2·67, P = 0·023). We found no association between recent cytotoxic chemotherapy or anti-CD19/anti-CD20 treatment and increased risk of death within the limitations of the cohort size. Therefore, disease control is an important factor predicting mortality in the context of SARS-CoV-2 infection alongside the possible risks of therapies such as cytotoxic treatment or anti-CD19/anti-CD20 treatments.",

keywords = "COVID-19, cancer treatments, haematological malignancies, Hematology, Multiple Myeloma/complications, Prospective Studies, COVID-19/complications, Humans, Risk Factors, Leukemia/complications, Male, Antigens, CD20/immunology, Adult, Female, Hematologic Neoplasms/complications, Antineoplastic Agents, Immunological/adverse effects",

author = "{UKCCMP team} and Stephen Booth and Curley, {Helen M} and Csilla Varnai and Roland Arnold and Lee, {Lennard Y W} and Campton, {Naomi A} and Gordon Cook and Karin Purshouse and James Aries and Andrew Innes and Cook, {Lucy B} and Oliver Tomkins and Oram, {Helen S} and Michael Tilby and Austin Kulasekararaj and David Wrench and Saoirse Dolly and Tom Newsom-Davies and Ruth Pettengell and Abigail Gault and Sam Moody and Sajjan Mittal and Mohammed Altohami and Tania Tillet and Jack Illingworth and Leena Mukherjee and Jane Apperly and John Ashcroft and Neil Rabin and Jonathan Carmichael and Jean-Baptiste Cazier and Rachel Kerr and Gary Middleton and Collins, {Graham P} and Claire Palles",

note = "Funding Information: The work was supported by University of Birmingham, University of Oxford, Blood Cancer UK (#20011). The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. This research was also supported by the National Institute for Health Research (NIHR) infrastructure at Leeds. Publisher Copyright: {\textcopyright} 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.",

year = "2022",

month = feb,

day = "9",

doi = "10.1111/bjh.17937",

language = "English",

volume = "196",

pages = "892--901",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley",

number = "4",

}

TY - JOUR

T1 - Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID-19

T2 - disease control as an important factor relative to recent chemotherapy or anti-CD20 therapy

AU - UKCCMP team

AU - Booth, Stephen

AU - Curley, Helen M

AU - Varnai, Csilla

AU - Arnold, Roland

AU - Lee, Lennard Y W

AU - Campton, Naomi A

AU - Cook, Gordon

AU - Purshouse, Karin

AU - Aries, James

AU - Innes, Andrew

AU - Cook, Lucy B

AU - Tomkins, Oliver

AU - Oram, Helen S

AU - Tilby, Michael

AU - Kulasekararaj, Austin

AU - Wrench, David

AU - Dolly, Saoirse

AU - Newsom-Davies, Tom

AU - Pettengell, Ruth

AU - Gault, Abigail

AU - Moody, Sam

AU - Mittal, Sajjan

AU - Altohami, Mohammed

AU - Tillet, Tania

AU - Illingworth, Jack

AU - Mukherjee, Leena

AU - Apperly, Jane

AU - Ashcroft, John

AU - Rabin, Neil

AU - Carmichael, Jonathan

AU - Cazier, Jean-Baptiste

AU - Kerr, Rachel

AU - Middleton, Gary

AU - Collins, Graham P

AU - Palles, Claire

N1 - Funding Information: The work was supported by University of Birmingham, University of Oxford, Blood Cancer UK (#20011). The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. This research was also supported by the National Institute for Health Research (NIHR) infrastructure at Leeds. Publisher Copyright: © 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.

PY - 2022/2/9

Y1 - 2022/2/9

N2 - Patients with haematological malignancies have a high risk of severe infection and death from SARS-CoV-2. In this prospective observational study, we investigated the impact of cancer type, disease activity, and treatment in 877 unvaccinated UK patients with SARS-CoV-2 infection and active haematological cancer. The primary end-point was all-cause mortality. In a multivariate analysis adjusted for age, sex and comorbidities, the highest mortality was in patients with acute leukaemia [odds ratio (OR) = 1·73, 95% confidence interval (CI) 1·1-2·72, P = 0·017] and myeloma (OR 1·3, 95% CI 0·96-1·76, P = 0·08). Having uncontrolled cancer (newly diagnosed awaiting treatment as well as relapsed or progressive disease) was associated with increased mortality risk (OR = 2·45, 95% CI 1·09-5·5, P = 0·03), as was receiving second or beyond line of treatment (OR = 1·7, 95% CI 1·08-2·67, P = 0·023). We found no association between recent cytotoxic chemotherapy or anti-CD19/anti-CD20 treatment and increased risk of death within the limitations of the cohort size. Therefore, disease control is an important factor predicting mortality in the context of SARS-CoV-2 infection alongside the possible risks of therapies such as cytotoxic treatment or anti-CD19/anti-CD20 treatments.

AB - Patients with haematological malignancies have a high risk of severe infection and death from SARS-CoV-2. In this prospective observational study, we investigated the impact of cancer type, disease activity, and treatment in 877 unvaccinated UK patients with SARS-CoV-2 infection and active haematological cancer. The primary end-point was all-cause mortality. In a multivariate analysis adjusted for age, sex and comorbidities, the highest mortality was in patients with acute leukaemia [odds ratio (OR) = 1·73, 95% confidence interval (CI) 1·1-2·72, P = 0·017] and myeloma (OR 1·3, 95% CI 0·96-1·76, P = 0·08). Having uncontrolled cancer (newly diagnosed awaiting treatment as well as relapsed or progressive disease) was associated with increased mortality risk (OR = 2·45, 95% CI 1·09-5·5, P = 0·03), as was receiving second or beyond line of treatment (OR = 1·7, 95% CI 1·08-2·67, P = 0·023). We found no association between recent cytotoxic chemotherapy or anti-CD19/anti-CD20 treatment and increased risk of death within the limitations of the cohort size. Therefore, disease control is an important factor predicting mortality in the context of SARS-CoV-2 infection alongside the possible risks of therapies such as cytotoxic treatment or anti-CD19/anti-CD20 treatments.

KW - COVID-19

KW - cancer treatments

KW - haematological malignancies

KW - Hematology

KW - Multiple Myeloma/complications

KW - Prospective Studies

KW - COVID-19/complications

KW - Humans

KW - Risk Factors

KW - Leukemia/complications

KW - Male

KW - Antigens, CD20/immunology

KW - Adult

KW - Female

KW - Hematologic Neoplasms/complications

KW - Antineoplastic Agents, Immunological/adverse effects

UR - http://www.scopus.com/inward/record.url?scp=85118921775&partnerID=8YFLogxK

U2 - 10.1111/bjh.17937

DO - 10.1111/bjh.17937

M3 - Article

C2 - 34761389

SN - 0007-1048

VL - 196

SP - 892

EP - 901

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 4

ER -

Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID-19: disease control as an important factor relative to recent chemotherapy or anti-CD20 therapy

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Fingerprint

Cite this